A Trial of Inflammatory Markers, Depressive Symptoms, and Heart Disease (CHIME)
A Randomized Controlled Trial of Inflammatory Markers, Depressive Symptoms, and Heart Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Department of General Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 - 60
- Mild depression
- Inflammatory markers: CRP > 2
Exclusion Criteria:
- Non-English or Non-Spanish speakers
- Active suicidal or homicidal ideation
- Current alcohol or other substance abuse
- Psychotic features
- Current personality disorder
- History of bipolar depressive disorder
- Any current psychotic disorder
- Current major depressive disorder
- Current depression treatment or treatment within preceding 6 weeks
- History of chronic liver and/or renal disease
- Current use or contraindication to any of the tested medications
- Absence of a response to a previous adequate trial of any of the tested medications
- Pregnant or lactating women
- History of coronary artery disease
- Current use of statins
- Current, regular aspirin use
- Antibiotic use within the previous four weeks
- History of diabetes
- Inflammatory diseases
- Meets NCEP guidelines for cholesterol lowering therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: 1
Patients randomized to sertraline will receive 50 mg/d for the first 6 weeks.
Based on clinical response and tolerability, the dosage will be increased to 2 tablets (100 mg/d) at the end of week 6 until the end of the study (8 weeks).
If AEs occur, the dosage will be reduced by 50 mg (1 tablet) at a time, as long as a minimum daily dose of 50 mg is maintained.
The psychiatry fellow will be responsible for drug administration and will see all patients weekly.
All randomized patients will also be seen at the mid-treatment, post-treatment, and follow-up visits by the study psychiatrist to determine depression symptom severity (HAM-D), assess medical tolerance to the study medications, and ensure patient psychiatric safety.
The study psychiatrist will be blinded to treatment allocation.
|
Patients randomized to sertraline will receive 50 mg/d for the first 6 weeks.
Based on clinical response and tolerability, the dosage will be increased to 2 tablets (100 mg/d) at the end of week 6 until the end of the study (8 weeks).
If adverse events occur, the dosage will be reduced by 50 mg (1 tablet) at a time, as long as a minimum daily dose of 50 mg is maintained.
|
|
Placebo Comparator: 2
To ensure blinding of research assessments and the patient, all medications, including the placebo, will be reformulated into a matching number of identical-appearing pills.
All randomized patients will also be seen at the mid-treatment, post-treatment, and follow-up visits by the study psychiatrist to determine depression symptom severity (HAM-D), assess the medical tolerance to the study medications (including placebo), and ensure patient psychiatric safety.
The study psychiatrist will be blinded to treatment allocation.
|
The placebo drug will be administered for 8 weeks.
To ensure blinding of research assessments and the patient, all medications, including the placebo, will be reformulated into a matching number of identical-appearing pills.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Score on Beck Depression Inventory and C-Reactive Protein Level at weeks 4, 8, and 12
Time Frame: 3 months
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Karina W Davidson, PhD, Columbia University: Behavioral Cardiovascular Health and Hypertension Program
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Myocardial Ischemia
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Coronary Disease
- Heart Diseases
- Depression
- Coronary Artery Disease
- Acute Coronary Syndrome
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Sertraline
- Simvastatin
Other Study ID Numbers
Other Study ID Numbers
- 4976 (Davidson)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.